Among the drugs used in conditioning regimens for stem cell transplantation, high-dose melphalan (HDM) plays an important role for both its strong myeloablative effect and for its favourable dose-response ratio. Here we report five cases of high frequency atrial fibrillation (AF) developing after HDM. Duration of the arrhythmia was always very short, beginning at variable intervals after the administration of HDM, in the absence of other factors potentially able to trigger AF. In all patients sinus rhythm was restored within 72 h and the follow-up did not show any cardiac damage. To the best of our knowledge, this side-effect has never been reported to occur after HDM.
Among the drugs used in conditioning regimens for peripheral blood progenitor cell transplantation (PBPCT), highdose melphalan (HDM) given intravenously plays an important role for both its myeloablative efficacy and for its very favourable dose-response curve. 1 Melphalan is an alkylating agent with a wide spectrum of activity against many hematological malignancies and solid tumors. [2] [3] [4] [5] This agent, when given at doses ranging from 50 to 100 mg/m 2 , has proved to be very effective but also extremely myelotoxic in multiple myeloma treated without stem cell rescue. [6] [7] [8] [9] Thereafter, the use of stem cells rescue has allowed an increase in the dose of melphalan used in combination chemotherapy regimens for lymphoma (eg BEAM) 10 and alone, [11] [12] [13] or even associated with TBI for multiple myeloma. 14, 15 When used at doses ranging from 140 to 200 mg/m 2 melphalan is well tolerated, with a dose-limiting toxicity mainly characterized by mucositis. 16 This property, associated with its very short in vivo half-life makes the use of melphalan preferable to high-dose cyclophosphamide in myeloablative regimens, which is an alkylating agent associated with cardiotoxicity. 17 Indeed, to date, no reports have been published concerning cardiotoxic events relating to the use of HDM, although this should be investigated Correspondence: Dr A Olivieri, Clinica di Ematologia Università di Ancona Ospedale Regionale Torrette, 60020 Ancona, Italy Received 12 September 1997; accepted 17 December 1997 because it could be a limiting factor in the use of HDM in patients with heart diseases.
We describe five cases with well-documented acute reversible cardiotoxicity out of 76 patients conditioned with HDM.
Patients and methods
We transplanted 76 patients with regimens including HDM at doses ranging from 120 to 200 mg/m ). For the remaining four patients (5.5%) conditioning regimens included the association of melphalan 140 mg/m 2 and TBI (1200 cGy in six fractions, at a dose rate of 5 cGy/min over three days) (Table 1) .
In all patients HDM was administered intravenously on day −2 (48 h before PBPC reinfusion) using a central venous catheter (CVC), 15 min immediately after reconstitution with buffer solution containing 60% w/v propylene glycol with sodium citrate and ethanol. In all cases melphalan (vials of 50 mg each) was kindly provided by Glaxo-Welcome (Verona, Italy) free of charge. The CVC position was checked by chest X-ray. Fifteen minutes before HDM administration all paients received ondansetron 8 mg i.v.
None of the patients receiving HDM received large fluid volumes (Ͼ3000 ml/24 h) or furosemide in order to force diuresis.
Three patients received bone marrow alone harvested under general anesthesia and 73 patients received PBPC mobilized with G-CSF after priming with cyclophosphamide 7 g/m 2 (42 patients), 18 DHAP regimen (21 patients), 19 etoposide 2 g/m 2 (six patients) 20 or VACOP-B regimen (four patients).
Concomitant routine prophylactic medication included ciprofloxacin (500 mg orally twice daily), fluconazole (200 mg orally once daily) and acycloguanosine 10 mg/kg i.v. in two divided doses daily starting from day −1. Phenobarbital 100 mg orally once daily was administered as prophylaxis against seizures in only those patients receiving busulphan or TBI.
All patients were scheduled for transplantation according to the following general criteria: good performance status (0 or 1 ECOG), absence of severe aberrations liver (total The PBPC infusion was performed after premedication with clorfenamine (10 mg i.v. in 10 min), after thawing the bags in a waterbath at 37°C, using a blood filter and a silicone CVC (Hohn of BARD, Salt Lake City, UT, USA); a median of 160 ml/patient (range 60-240) was reinfused containing 10% of DMSO (16 ml/patient; range 6-24). PBPCs were cryopreserved by adding an equal volume of cryoprotective solution containing DMSO 20% and human albumin 8% and using a controlled rate modified Planer R201 freezing device.
All five patients who developed AF underwent a followup after transplantation including the folowing tests: exercise test, dynamic ECG (Holter), Doppler and mono-twodimensional echocardiography.
All linear measurements were performed with a monodimensional technique, according to the recommendations of American Society of Echocardiography. 21 The data analyzed included left atrium telesystolic diameter, left ventricular internal diameter in diastole (LVIDd), left ventricular internal diameter in systole (LVIDs), interventricular septal thickness (IVSTd) and posterior wall thickness (PWTd). The above parameters were used to calculate the ejection fraction and the left ventricular mass (LVMi) as previously described. 22 The Doppler examination of transvalve fluxes was accomplished by apical projection in order to exclude pending valvular regurgitation.
Case reports
Among the 76 patients transplanted with HDM, we observed the onset of high frequency atrial fibrillation (AF) never associated with haemodynamic disturbance or ischaemic heart disease in five cases. In a control group of 36 patients autotransplanted with conditioning regimens not including HDM we observed no arrhythmias. These two groups of patients, observed during the same period, were matched for age, sex and number of pretransplant chemotherapy courses ( Table 2) .
The duration of arrhythmia was very short, beginning at variable intervals (26-297 h) from the administration of HDM and no relationship was found between AF and concomitant medications used. In all patients O 2 saturation myocardial enzymes, electrolytes, venous Ph, T3, T4 and TSH serum levels were all normal. Chest X-ray was normal and neither fever nor bacteremia were documented before or during AF. In all patients except one, the AF quickly responded to propanfenone i.v. and sinus rhythm was reestablished within 72 h. The main characteristics of the five patients developing AF after HDM are shown in Table 3 .
Case 1 (UPN 56)
A 62-year-old man with multiple myeloma received HDM 360 mg on day −2 and 26 h later he developed highfrequency AF. During the AF he underwent echocardiography, thyroid function and functional respiratory tests; all investigations were negative. He received propanfenone as a 2 mg/kg bolus followed by 1 mg/min continuous i.v. infusion over 2 h. He then received the same drug orally: 300 mg every 8 h; normal sinus rhythm was achieved 70 h after the onset of the arrhythmia.
Six months later, the patient underwent a second autologous PBPCT with melphalan 120 mg/m 2 plus busulphan 12 mg/m 2 , continuing the prophylaxis with oral propanfenone and no cardiac toxicity was observed.
Case 2 (UPN 58)
A 64-year-old man with NHL received conditioning regimen including TBI plus HDM 220 mg. During TBI 1051 Table 3 Patients developing atrial fibrillation after HDM (1200 cGy divided into six fractions days −5 to −3), he was monitored twice a day by ECG, venous pH and O 2 saturation. On day −2 he received melphalan (220 mg), and on day 0 thawed PBPC. Seventy-one hours after the administration of HDM he developed high-frequency AF (rate 150 b.p.m.) and he was immediately treated with propanfenone as previously described. After 4 h he achieved normal sinus rhythm.
UPN

Case 3 (UPN 76)
A 63-year-old woman with multiple myeloma developed high-frequency AF 73 h after conditioning regimen consisting of HDM 325 mg administered on day −2. Chest Xray was normal and echocardiography was not performed during AF. The patient was treated with propanfenone 2 mg/kg as a bolus followed by 1 mg/kg over 2 h. The arrhythmia lasted for 5 h without signs or symptoms of hemodynamic disturbance; however prophylactic therapy with oral propanfenone was given. This patient had a previous history of atrial flutter which had appeared during priming with high-dose cyclophosphamide (7 g/m 2 ). After 4 months, a second autologous PBPCT was performed and 9 months afterwards, the patient was disease-free, without signs or symptoms of cardiopathy.
Case 4 (UPN 101)
A 54-year-old man with multiple myeloma received melphalan 340 mg i.v. on day −2 before the infusion of PBPC. On day +12 after the administration of the alkylating agent he developed atrial fibrillation and treatment with propanfenone as previously described was started. This therapy did not affect normal sinus rhythm and amiodarone 5 mg/kg i.v. bolus was administered with normalization of the ECG after 44 h.
The patient is alive, 9 months after transplantation, in partial remission without signs or symptoms of cardiopathy.
Case 5 (UPN 107)
A 47-year-old man with NHL developed the arrhythmia on the day of reinfusion of PBPC (day 0) after conditioning with thiotepa 1000 mg on day −4 and HDM 300 mg on day −2. He developed atrial fibrillation 44 h after the administration of melphalan and sinus rhythm was spontaneously re-established 4 h afterwards. This patient died 3 months after transplantation for progressive disease, but without any signs of cardiac involvement or underlying structural cardiac damage.
In all five patients chest X-ray performed before the cardiac arrhythmia developed was negative and T3, T4 and TSH serum levels were normal. During the follow-up after transplantation echocardiography was performed in all patients except one (case number 5) and it showed a normal ejection fraction, normal morphology of the mitral valve and no enlargement of the atria or ventricles. No obvious alterations of echogenicity or cardiac volume (restrictive pattern) suggestive of amyloid infiltration were detected. Lastly, none of the patients we examined showed noticeable alterations in cardiac flow; exercise tests were also negative for coronary artery disease in all four patients and the dynamic ECG (Holter) showed no evidence of significant dysrhythmia or ischaemia.
Discussion
In all five patients who developed AF, this arrhythmia arose in absence of a detectable structural heart disease; indeed before the onset of AF no patients had shown signs or symptoms of cardiopathy and only patient number 3 had previously developed paroxysmal atrial flutter after the administration of cyclophosphamide 7 g/m 2 . All five patients underwent further examination soon after the AF and four of them also 1 year after transplantation; even in this case, we found no alterations in cardiac kinetics or in cardiac morphology assessed by echocardiography; in particular, we found no evidence of myocardial amyloid. The exercise test and the dynamic ECG (Holter) showed no evidence of asymptomatic ischaemic heart disease. Finally, before starting the conditioning regimen with HDM, none of the five patients had any predisposing factors for AF such as hyperthyroidism, constrictive pericarditis, a mediastinal mass, acute or chronic respiratory disease.
We were also unable to demonstrate any intercurrent conditions potentially triggering AF: fever, septicemia, electrolyte imbalance or significant haemodynamic alterations.
As regards iatrogenic factors potentially correlated with AF development, all patients had a CVC inserted 24 h before the start of high-dose therapy and none underwent another surgical intervention; in all patients the chest Xray showed that the CVC was in the superior vena cava.
The infusion of cryopreserved PBPC has been reported to be potentially associated with bradyarrhythmias and other cardiovascular changes but not with AF; 23 only patient number 5 developed AF 4 h before the PBPC reinfusion.
All drugs administered to the five patients during the 10 days before the onset of AF were studied both for interactions and for potential side-effects, by cross checking at least 15 items on Med-line (onco-disc and hemato-disc) and finally by consulting the PDR. 24 As regards the drugs administered, only ciprofloxacin was found to be associated with sinus tachycardia or atrial flutter (with a frequency of less than 1%); also, we cannot completely exclude that in one patient (case number 2) TBI may have contributed to the AF and that high-dose thiotepa in another patient (case number 5) could have similarly induced an additive cardiotoxic effect.
In the remaining three patients HDT was only with HDM and AF started at variable intervals (26, 73 and 297 h, respectively) after the administration of this drug. These variable intervals could be explained by the extreme intrapatient variability of melphalan pharmacokinetics parameters that can be prospectively confirmed by determining the AUC and t . ␣ and t . ␤ in every patient. Indeed, after i.v. administration, HDM shows a biphasic distribution with a very wide AUC (from 146 to 1515 mg/min/ml); it is rapidly hydrolized to non-cytotoxic dihydroxy metabolites 16 but no information is available about the arrhythmogenic potential of these compounds. Moreover, the plasma clearance of HDM ranges from 92 to 961 ml/min/ 2 , while age apparently does not influence the HDM pharmacokinetics. 25 Although one patient developed AF 297 h after HDM administration, it is only possible to hypothesize that the onset of this cardiotoxic event was related to this drug. However, there are many other examples of toxic events occurring when plasma levels of the drug responsible are undetectable, because the biologic half-life is very different from the plasma half-life.
Before this report, only two patients treated with HDM were reported to have developed cardiac toxicity: Moreau et al 26 described one case of grade 2 pericarditis and one case of grade 2 dysrhythmia, not further specified. This author treated 16 patients with HDM i.v. at the dosage of 220 mg/m 2 followed by PBSC rescue and the most important side-effect was mucositis in 81% of patients.
The majority of the 76 patients who underwent HDM in our Institution showed good extrahematological tolerance; the major adverse effect was mild or severe mucositis (III WHO score) in almost all patients, occurring 3-5 days after the drug. We did not observe any other toxic events during the 72 h following drug infusion.
HDM seems to be less toxic than high-dose cyclophosphamide; the latter can be responsible for refractory and often fatal congestive heart failure. The pathologic findings are hemorrhagic endocarditis associated with hemorrhagic myocarditis. 17 In conclusion, this is the first report concerning acute conduction cardiotoxicity after conditioning regimens including HDM. In our experience HDM given intravenously is generally well tolerated up to a 200 mg/m 2 dose; the acute cardiotoxicity is a quite unexpected sideeffect.
The frequency of this adverse event seems to be significant (6.6% overall); however, if we consider only patients receiving HDM alone the absolute frequency of AF in this group is 33%, and 22% excluding the patient who developed AF after 297 h.
Perhaps this relatively high incidence of dysrhythmia can be attributed to the relatively high mean age of our transplant population even though this was not significantly different in a comparable group of patients not receiving HDM. It is also of note that in the group transplanted with HDM there was a higher frequency of patients with multiple myeloma who had been previously treated with CTX 7 g/m 2 ; thus, it cannot be completely excluded that the previous administration of CTX facilitated the AF in patients number 1, 3 and 4.
AF has never been associated with documented acute or chronic structural heart damage; moreover, long-term follow-up of the evaluable patients shows no evidence of organic heart damage.
Studies are necessary to look into the possible relationship between HDM and acute cardiotoxicity, but HDM administration should be carefully planned in patients with a previous history of heart disease.
